目的:探讨前列倍喜胶囊加а受体阻滞剂(naftopidil)治疗慢性前列腺炎/慢性骨盆疼痛综合征(CP/CPPS)的临床疗效。方法:按前列腺炎诊断治疗指南标准［1］选出符合CP/CPPS患者96例,采用随机双盲对照,分为治疗组和对照组。治疗组(56例)服用前列倍喜胶囊加а-受体阻滞剂;对照组(40例)服用а-受体阻滞剂加安慰剂;疗程为6周。配合前列腺按摩,每周一次,然后观察其疗效。结果:治疗组56例患者,显效16例,有效34例,无效6例。总有效率89.3%(50/56);对照组40例患者,显效4例,有效24例,无效12例。总有效率70.0%(28/40)。两组疗效比较有统计学意义(Plt;0.05);治疗组治疗前后NIH-CPSI各项指标比较有显著性统计学意义(Plt;0.01);对照组治疗前后NIH-CPSI各项指标比较有统计学意义(Plt;0.05),两组治疗前后NIH-CPSI比较有统计学意义(Plt;0.05)。结论:前列倍喜胶囊加а-受体阻滞剂联合治疗CP/CPPS安全有效。
Objective To explore the effect of vascular endothelial growth factor-C (VEGF-C) gene transfection on the expression level of VEGF-C in human breast cancer MCF-7 cell. Methods The constructed VEGF-C gene eukaryotic expression vector was transfected into the human breast cancer MCF-7 cell by using lipofectamine transfection reagents， and the positive cell clones were obtained through G418 selection after transfection. The expressions of VEGF-C mRNA and protein were detected by RT-PCR and Western blot respectively. Results Following the transfection of the VEGF-C recombination plasmid, there were significant differences on the expression levels of VEGF-C mRNA and protein between pcDNA3.1-VEGF-C transfection group and pcDNA3.1 transfection group （12.382±2.183 vs 6.039±1.950, P＜0.01; 0.971±0.186 vs 0.594±0.196, P＜0.05). Conclusion With the transfection of pcDNA3.1-VEGF-C vector by using the liposome, the expression levels of VEGF-C mRNA and protein rise up in breast cancer MCF-7 cell.